printemailclick to share buttonfacebooktwitterlinkedin
Gastrointestinal Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)

Gastrointestinal cancers encompass the esophagus, stomach, bowel and rectum, liver, and pancreas.

The Gastrointestinal Disease Site Group (GI DSG) produces evidence-based reports to assist practitioners and patients make decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports.   

The PEBC has a formal and standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance. The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ) or the lead author of the document.

Neuroendocrine Tumours

  • Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours
    GL 2-21 : December 2016
    Status: CURRENT

Anal Cancer

  • Management of Squamous Cell Cancer of the Anal Canal
    2-8 EBS Version 2: February 2014
    Status: CURRENT

Colorectal Cancer

  • The Use of Leucovorin in Colorectal Cancer
    12-17 ES: February 2016
    Status: CURRENT
  • Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection
    Guideline 2-29 Version 2: September 2015
    Status: CURRENT
  • Strategies of Sequential Therapies in Unresectable, Metastatic Colorectal Cancer Treated with Palliative Intent
    2-5 EBS: January 2014
    Status: CURRENT
  • Optimization of Preoperative Assessment in Patients Diagnosed with Rectal Cancer
    17-8 EBS: January 2014
    Status: CURRENT
  • Continuous versus Intermittent Chemotherapy Strategies in Inoperable, Advanced Colorectal Cancer
    2-6 EBS: January 2014
    Status: CURRENT
  • Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
    2-4 Version 2 EBS: November 2013
    Status: IN REVIEW 


  • Preoperative or Postoperative Therapy for Resectable Esophageal Cancer
    2-11 EBS Version 4: June 2016 
    Status: CURRENT


  • Staging and Surgical Approaches in Gastric Cancer
    Guideline 2-19: January 2017
    Status: CURRENT
  • Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer
    2-14 PG Version 3.2011: April 2011
    Status: CURRENT
  • Systemic Therapy for Advanced Gastric Cancer
    2-26 EBS Version 2: May 2014
    Status: IN REVIEW 

For Education and Information Purposes 

  • Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus 
  • The Treatment of Locally Advanced Pancreatic Cancer
  • Chemotherapy or Radiotherapy for Resectable Pancreatic Adenocarcinoma
  • The Use of FOLFIRINOX as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma
  • The Role of Bevacizumab (Avastin TM ) Combined with Chemotherapy in the Treatment of Patients With Advanced Colorectal Cancer
  • Follow-up of Patients with Curatively Resected Colorectal Cancer
  • Use of Gemcitabine in the Treatment of Advanced Pancreatic Adenocarcinoma
  • Oral Capecitabine (XelodaTM) in the First-line Treatment of Metastatic Colorectal Cancer 
  • Use of Irinotecan in the Second-Line Treatment of Metastatic Colorectal Carcinoma
  • Use of Irinotecan (Camptosar®, CPT-11) Combined with 5-Fluorouracil and Leucovorin (5FU/LV) as First-line Therapy for Metastatic Colorectal Cancer 
  • Use of Raltitrexed (TomudexTM) in the Management of Metastatic Colorectal Carcinoma
  • The Role of Oxaliplatin Combined with 5-Fluorouracil and Folinic Acid in the First and Second-Line Treatment of Advanced Colorectal Cancer 
Program in Evidence-Based Care (PEBC)
McMaster University, Juravinski Site
G Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Last modified: Tue, May 30, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?